Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1436032 in IDH1-mutant advanced solid tumors
NCT02746081Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of BAY1436032 in solid tumor, anaplastic glioma, glioblastoma (GBM) and 1 more, sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose at 21 days, Number of participants with adverse events up to 30 months and 1 more. Started May 2016; status: completed.
02
Drugs
BAY1436032
03
Conditions
solid tumoranaplastic gliomaglioblastoma (GBM)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT02746081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02746081.